|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 29th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 29th, 2022 11:49AM
|
Aug 29th, 2022 11:49AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 28th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 28th, 2022 04:48AM
|
Aug 28th, 2022 04:48AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 27th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 27th, 2022 04:08AM
|
Aug 27th, 2022 04:08AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 25th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 25th, 2022 08:48AM
|
Aug 25th, 2022 08:48AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 23rd, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 23rd, 2022 10:41AM
|
Aug 23rd, 2022 10:41AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 21st, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 21st, 2022 12:25PM
|
Aug 21st, 2022 12:25PM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 20th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 20th, 2022 02:01PM
|
Aug 20th, 2022 02:01PM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 19th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 19th, 2022 12:24PM
|
Aug 19th, 2022 12:24PM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 18th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 18th, 2022 04:08AM
|
Aug 18th, 2022 04:08AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:ctic
|
https://www.indeed.com/cmp/cti-biopharma-corp
|
Aug 17th, 2022 12:00AM
|
Open
|
CTI BioPharma Corp
|
|
Pharmaceutical & Biotechnology
|
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
|
|
3101 Western Ave., #800 Seattle, WA 98121
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00
|
10.00
|
3.20
|
4.10
|
2.40
|
2.70
|
3.30
|
|
|
|
|
|
|
|
|
|
Aug 17th, 2022 09:47AM
|
Aug 17th, 2022 09:47AM
|
CTI BioPharma
|
Health Care
|
Health Care Equipment & Services
|